Skip to content
Healthcare Innovation ›

Gene therapy, mRNA platforms and next-generation biologics.

Active institutional funds added a net $11.1 billion in Q2 2026, versus $5.0 billion in Q1 2026 — an inflow 122% larger. 69.2% of companies in this theme saw increased active positions in Q2 2026.

Ecosystem Map

CAR-T and other cell-based therapies for cancer and autoimmune diseases.

64 companiesExplore

CRISPR and viral vector platforms for genetic disease treatment.

43 companiesExplore

Messenger RNA technology for vaccines and therapeutic applications.

6 companiesExplore

Bottleneck Tracker

2026
Current
2026
Current
2026
Current
2026
Current

Bottleneck details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.